L Bach-Rojecky
Overview
Explore the profile of L Bach-Rojecky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
184
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bach-Rojecky L, Lackovic Z
Pharmazie
. 2021 Oct;
76(10):519-521.
PMID: 34620283
The discovery of bacterial viruses able to kill bacteria, named bacteriophages (phages), more than a century ago, contributed to combating bacterial infections during the first three decades of the 20th...
2.
Drinovac Vlah V, Filipovic B, Bach-Rojecky L, Lackovic Z
Eur J Pain
. 2017 Nov;
22(3):583-591.
PMID: 29134730
Background: Although botulinum toxin type A (BT-A) is approved for chronic migraine treatment, its site and mechanism of action are still elusive. Recently our group discovered that suppression of CGRP...
3.
Drinovac Vlah V, Bach-Rojecky L, Lackovic Z
J Neural Transm (Vienna)
. 2016 Aug;
123(12):1403-1413.
PMID: 27506955
"Mirror pain" or mirror-image pain (MP) is pain opposite to the side of injury. Mechanism and frequency in humans are not known. There is no consent on therapy. Here we...
4.
Drinovac V, Bach-Rojecky L, Lackovic Z
J Neural Transm (Vienna)
. 2014 Jan;
121(6):665-9.
PMID: 24420081
The mechanism of botulinum toxin type A (BTX-A) antinociceptive action in the central nervous system is little known. The potential interaction between BTX-A and GABAergic system has not been investigated...
5.
Drinovac V, Bach-Rojecky L, Matak I, Lackovic Z
Neuropharmacology
. 2013 Mar;
70:331-7.
PMID: 23499661
Botulinum toxin A (BTX-A) is approved for treatment of chronic migraine and has been investigated in various other painful conditions. Recent evidence demonstrated retrograde axonal transport and suggested the involvement...
6.
Matak I, Bach-Rojecky L, Filipovic B, Lackovic Z
Neuroscience
. 2011 May;
186:201-7.
PMID: 21539899
Botulinum toxin A (BTX-A) is approved for treatment of different cholinergic hyperactivity disorders, and, recently, migraine headache. Although suggested to act only locally, novel observations demonstrated bilateral reduction of pain...
7.
Tahirovic I, Sofic E, Sapcanin A, Gavrankapetanovic I, Bach-Rojecky L, Salkovic-Petrisic M, et al.
J Neural Transm Suppl
. 2007 Nov;
(72):235-40.
PMID: 17982899
It is believed that oxidative stress plays a central role in the pathogenesis of metabolic diseases like diabetes mellitus (DM) and its complications (like peripheral neuropathy) as well as in...
8.
Bach-Rojecky L, Relja M, Lackovic Z
J Neural Transm (Vienna)
. 2005 Jan;
112(2):215-9.
PMID: 15657640
A peripheral application of botulinum toxin type A (7 U/kg) has significantly reduced thermal and mechanical hypersensitivity in rats with the partial sciatic nerve transection as a classical model of...